Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

BACKGROUND: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate...

Descripción completa

Detalles Bibliográficos
Autores principales: Datoo, Mehreen S, Natama, Magloire H, Somé, Athanase, Traoré, Ousmane, Rouamba, Toussaint, Bellamy, Duncan, Yameogo, Prisca, Valia, Daniel, Tegneri, Moubarak, Ouedraogo, Florence, Soma, Rachidatou, Sawadogo, Seydou, Sorgho, Faizatou, Derra, Karim, Rouamba, Eli, Orindi, Benedict, Ramos Lopez, Fernando, Flaxman, Amy, Cappuccini, Federica, Kailath, Reshma, Elias, Sean, Mukhopadhyay, Ekta, Noe, Andres, Cairns, Matthew, Lawrie, Alison, Roberts, Rachel, Valéa, Innocent, Sorgho, Hermann, Williams, Nicola, Glenn, Gregory, Fries, Louis, Reimer, Jenny, Ewer, Katie J, Shaligram, Umesh, Hill, Adrian V S, Tinto, Halidou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121760/
https://www.ncbi.nlm.nih.gov/pubmed/33964223
http://dx.doi.org/10.1016/S0140-6736(21)00943-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121760/
https://www.ncbi.nlm.nih.gov/pubmed/33964223
http://dx.doi.org/10.1016/S0140-6736(21)00943-0

Ejemplares similares